• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Corticosteroid-Sparing Effects of Treatment With Guselkumab in Patients With Moderately to Severely Active CD: Phase 3 GRAVITI Study Results Through Week 48.古塞库单抗治疗中度至重度活动性克罗恩病患者的糖皮质激素节省效应：3期GRAVITI研究第48周结果
Gastroenterol Hepatol (N Y). 2025 Aug;21(7 Suppl 5):10-12.
2
Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI Study.古塞库单抗皮下注射诱导和维持治疗中度至重度活动性克罗恩病患者的疗效和安全性：3期GRAVITI研究结果
Gastroenterology. 2025 Aug;169(2):308-325. doi: 10.1053/j.gastro.2025.02.033. Epub 2025 Mar 18.
3
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials.古塞库单抗静脉诱导和皮下维持治疗克罗恩病患者的疗效和安全性（GALAXI-2和GALAXI-3）：两项3期、随机、安慰剂和活性对照药对照、双盲、三模拟试验的48周结果
Lancet. 2025 Jul 26;406(10501):358-375. doi: 10.1016/S0140-6736(25)00681-6. Epub 2025 Jul 17.
4
One-Year Efficacy of Guselkumab Versus Advanced Therapies for the Treatment of Moderately to Severely Active Crohn's Disease: A Network Meta-Analysis.古塞库单抗与先进疗法治疗中度至重度活动性克罗恩病的一年疗效：一项网状Meta分析。
Adv Ther. 2025 Jun;42(6):2708-2727. doi: 10.1007/s12325-025-03183-x. Epub 2025 May 6.
5
Guselkumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients: results of the phase III randomized placebo-controlled PROTOSTAR study.古塞库单抗治疗儿童中重度斑块状银屑病：III期随机安慰剂对照PROTOSTAR研究结果
Br J Dermatol. 2025 Mar 18;192(4):618-628. doi: 10.1093/bjd/ljae502.
6
Guselkumab in East Asians With Moderate-to-Severe Ulcerative Colitis: Subgroup Analysis of the QUASAR Induction and Maintenance Studies.古塞库单抗治疗东亚中重度溃疡性结肠炎：QUASAR诱导和维持研究的亚组分析
J Gastroenterol Hepatol. 2025 Sep;40(9):2197-2208. doi: 10.1111/jgh.17036. Epub 2025 Jun 26.
7
Efficacy and safety of guselkumab in patients with active lupus nephritis: results from a phase 2, randomized, placebo-controlled study.古塞库单抗治疗活动性狼疮性肾炎患者的疗效和安全性：一项2期随机安慰剂对照研究的结果
Rheumatology (Oxford). 2025 May 1;64(5):2731-2740. doi: 10.1093/rheumatology/keae647.
8
Guselkumab Efficacy in Biologic-Naïve Participants with Psoriatic Arthritis and Severe Disease Activity: Post Hoc Analysis of a Phase 3 Study.古塞库单抗在初治的银屑病关节炎及严重疾病活动患者中的疗效：一项3期研究的事后分析
Rheumatol Ther. 2025 Jul 21. doi: 10.1007/s40744-025-00777-3.
9
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial.抗TL1A抗体阿非奇巴特治疗中度至重度活动性溃疡性结肠炎（TUSCANY-2）：一项多中心、双盲、全程治疗、多剂量、随机、安慰剂对照的2b期试验
Lancet Gastroenterol Hepatol. 2025 Jul 21. doi: 10.1016/S2468-1253(25)00129-3.
10
Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones: Cohort A of the VISIBLE Randomized Clinical Trial.古塞库单抗用于治疗各种肤色的中度至重度银屑病：VISIBLE随机临床试验的A队列
JAMA Dermatol. 2025 Jun 25. doi: 10.1001/jamadermatol.2025.1836.

本文引用的文献

1
Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI Study.古塞库单抗皮下注射诱导和维持治疗中度至重度活动性克罗恩病患者的疗效和安全性：3期GRAVITI研究结果
Gastroenterology. 2025 Aug;169(2):308-325. doi: 10.1053/j.gastro.2025.02.033. Epub 2025 Mar 18.

Corticosteroid-Sparing Effects of Treatment With Guselkumab in Patients With Moderately to Severely Active CD: Phase 3 GRAVITI Study Results Through Week 48.

出版信息

Gastroenterol Hepatol (N Y). 2025 Aug;21(7 Suppl 5):10-12.

PMID:40893185
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12397773/
Abstract
摘要